MRD signifies remaining cancer cells post-treatment, with interpretations varying by cancer type. MRD testing methods include flow cytometry and genomic tests, detecting residual cancer cells.

AUSTIN, Texas, January 15, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, will provide an update to the investment community, today, at the 43rd ...

Also in 2024, research using minimal residual disease (MRD) to monitor patients for relapse in drug trials took off, and pharmaceutical companies will continue to use the biomarker in their drug ...

Blood Cancer Discov (2025) 6 (1): 13–22. The acceptance of MRD-negative complete response as an endpoint that is reasonably likely to predict clinical benefit will allow for the design of streamlined ...